LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: A Prospective Multicenter Standard of Care Study of Outpatient Laparoscopic Sleeve Gastrectomy.

    Surve, Amit / Cottam, Daniel / Pryor, Aurora / Cottam, Samuel / Michaelson, Robert / Umbach, Thomas / Williams, Michael / Bagshahi, Hossein / July, Laura / Bueno, Racquel / Chock, Devorah / Apel, Matthew / Hart, Christopher / Johnson, William / Curtis, Brendon / Rosenbluth, Amy / Spaniolas, Konstantinos / Medlin, Walter / Wright, Whitney /
    Lee, Ciara / Lee, Christy / Trujeque, Rachael / Rinker, Deborah

    Obesity surgery

    2024  Volume 34, Issue 4, Page(s) 1122–1130

    Abstract: A global shift is occurring as hospital procedures move to ambulatory surgical settings. Surgeons have performed outpatient sleeve gastrectomy (SG) in bariatric surgery since 2010. However, prospective trials are needed to ensure its safety before ... ...

    Abstract A global shift is occurring as hospital procedures move to ambulatory surgical settings. Surgeons have performed outpatient sleeve gastrectomy (SG) in bariatric surgery since 2010. However, prospective trials are needed to ensure its safety before widespread adoption.
    Purpose: The study aimed to present a comprehensive report on the prospective data collection of 30-day outcomes of outpatient primary laparoscopic SG (LSG). This trial seeks to assess whether outpatient LSG is non-inferior to hospital-based surgery in selected patients who meet the outpatient surgery criteria set by the American Society for Metabolic and Bariatric Surgery.
    Materials and methods: This study is funded by the Society of American Gastrointestinal and Endoscopic Surgeons and has been approved by the Advarra Institutional Review Board (Pro00055990). Cognizant of the necessity for a prospective approach, data collection commenced after patients underwent primary LSG procedures, spanning from August 2021 to September 2022, at six medical centers across the USA. Data centralization was facilitated through ArborMetrix. Each center has its own enhanced recovery protocols, and no attempt was made to standardize the protocols.
    Results: The analysis included 365 patients with a mean preoperative BMI of 43.7 ± 5.7 kg/m
    Conclusion: The prospective cohort study suggests that same-day discharge following LSG seems safe in highly selected patients at experienced US centers.
    MeSH term(s) Humans ; Obesity, Morbid/surgery ; Prospective Studies ; Outpatients ; Standard of Care ; Laparoscopy/methods ; Bariatric Surgery/methods ; Gastrectomy/methods ; Postoperative Complications/etiology ; Retrospective Studies ; Treatment Outcome
    Language English
    Publishing date 2024-02-17
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 1070827-3
    ISSN 1708-0428 ; 0960-8923
    ISSN (online) 1708-0428
    ISSN 0960-8923
    DOI 10.1007/s11695-024-07094-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3381: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Comparative study between laparoscopic adjustable gastric banding and laparoscopic gastric bypass: single-institution, 5-year experience in bariatric surgery.

    Jan, Jay C / Hong, Dennis / Bardaro, Sergio Jose / July, Laura V / Patterson, Emma J

    Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

    2007  Volume 3, Issue 1, Page(s) 42–50; discussion 50–1

    Abstract: Background: Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB) are common surgical procedures for morbid obesity. Few single-institution studies have compared LRYGB and LAGB.: Methods: All patients ... ...

    Abstract Background: Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB) are common surgical procedures for morbid obesity. Few single-institution studies have compared LRYGB and LAGB.
    Methods: All patients underwent LRYGB or LAGB at Legacy Health System. The data for the study were obtained from a prospectively maintained database. Preoperatively, most patients were allowed to choose between LRYGB and LAGB. Age, gender, body mass index, complications, mortality, and weight loss were examined.
    Results: From October 2000 to October 2005, 492 patients underwent LRYGB and 406 patients underwent LAGB. The mean age was 44 +/- 10 and 47 +/- 11 years, respectively (P <.001). The mean preoperative body mass index was 49 +/- 8 and 51 +/- 9 kg/m(2) (P <.05). Patients undergoing LRYGB had longer operative times (134 +/- 41 min versus 68 +/- 26 min, P <.001) and longer hospital stays (2.5 +/- 3.5 d versus 1.1 +/- 1.1 d, P <.001). Blood loss was minimal in both groups. The percentage of excess weight loss was significantly better for patients who underwent LRYGB at all points of follow-up, except at 5 years. Total complications occurred in 32% of patients who underwent LRYGB and 24% of patients who underwent LAGB (P = .002). The 90-day mortality rate was .2% in both groups. The reoperation rate was the same (17%) in both groups.
    Conclusions: Patients undergoing LAGB had shorter operative times and shorter hospital stays compared with patients undergoing LRYGB. LAGB was associated with a lower complication rate. Early weight loss was significantly greater after LRYGB, but the data comparing long-term weight loss after LRYGB and LAGB have been inconclusive.
    MeSH term(s) Adult ; Female ; Gastric Bypass ; Gastroplasty ; Humans ; Laparoscopy ; Male ; Middle Aged ; Obesity, Morbid/surgery ; Postoperative Complications ; Treatment Outcome
    Language English
    Publishing date 2007-01
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 2274243-8
    ISSN 1878-7533 ; 1550-7289
    ISSN (online) 1878-7533
    ISSN 1550-7289
    DOI 10.1016/j.soard.2006.11.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6572: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy.

    July, Laura V / Akbari, Majid / Zellweger, Tobias / Jones, Edward C / Goldenberg, S Larry / Gleave, Martin E

    The Prostate

    2002  Volume 50, Issue 3, Page(s) 179–188

    Abstract: Introduction and objectives: Progression of prostate cancer to androgen independence (AI) results in part from the upregulation of anti-apoptotic genes following androgen withdrawal, and androgen-independent disease remains the primary obstacle to ... ...

    Abstract Introduction and objectives: Progression of prostate cancer to androgen independence (AI) results in part from the upregulation of anti-apoptotic genes following androgen withdrawal, and androgen-independent disease remains the primary obstacle to improved survival. Testosterone-repressed prostate message-2 (TRPM-2) encodes the anti-apoptotic protein clusterin, which is upregulated in response to cellular compromise as observed in normal and malignant tissues undergoing apoptosis. Systemic administration of antisense clusterin oligonucleotides in prostate cancer xenograft models delays progression to AI and enhances chemosensitivity. The objective of this study was to define changes in clusterin expression following neoadjuvant hormone therapy (NHT) in prostate cancer patients.
    Materials and methods: Archival radical prostatectomy (RP) specimens were obtained for 128 patients who received either no NHT or treatment for 2-8 weeks, 3 months, or 8 months. Paired needle biopsy specimens were acquired for 30 patients and all tissues were subjected to clusterin immunohistochemistry. Western blot analysis was performed on frozen tissue from 5 untreated and 5 treated patients.
    Results: Clusterin expression in malignant prostatic tissue was significantly greater in patients who underwent preoperative NHT (P < 0.001). Needle biopsies obtained prior to NHT consistently demonstrated lower staining intensity than corresponding RP specimens (P < 0.001). Western blot analysis confirmed clusterin levels increased 17-fold beginning within 4 weeks after androgen withdrawal.
    Conclusions: Upregulation of clusterin levels following androgen ablation therapy may represent an adaptive cell survival response following apoptotic signals like androgen withdrawal. These findings support clusterin as a valid therapeutic target in strategies employing novel multimodality therapy for advanced prostate cancer.
    MeSH term(s) Adult ; Aged ; Androgen Antagonists/administration & dosage ; Androgen Antagonists/pharmacology ; Apoptosis ; Biopsy ; Blotting, Western ; Cell Survival ; Clusterin ; Complement Inactivator Proteins/biosynthesis ; Disease Progression ; Glycoproteins/biosynthesis ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Molecular Chaperones/biosynthesis ; Neoadjuvant Therapy ; Prostatectomy ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Signal Transduction ; Time Factors ; Up-Regulation
    Chemical Substances Androgen Antagonists ; CLU protein, human ; Clusterin ; Complement Inactivator Proteins ; Glycoproteins ; Molecular Chaperones
    Language English
    Publishing date 2002-01-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604707-5
    ISSN 1097-0045 ; 0270-4137
    ISSN (online) 1097-0045
    ISSN 0270-4137
    DOI 10.1002/pros.10047
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1608: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

    July, Laura V / Beraldi, Eliana / So, Alan / Fazli, Ladan / Evans, Kenneth / English, John C / Gleave, Martin E

    Molecular cancer therapeutics

    2004  Volume 3, Issue 3, Page(s) 223–232

    Abstract: Introduction: Lung cancer is highly lethal and resistant to most anticancer interventions. Treatment resistance is mediated, in part, by enhanced expression of cell survival proteins that help facilitate tumor progression. Clusterin is a stress- ... ...

    Abstract Introduction: Lung cancer is highly lethal and resistant to most anticancer interventions. Treatment resistance is mediated, in part, by enhanced expression of cell survival proteins that help facilitate tumor progression. Clusterin is a stress-associated cytoprotective protein up-regulated by various apoptotic triggers in many cancers and confers treatment resistance when overexpressed. The objectives in this study were to evaluate clusterin expression levels in human lung cancer tissue, and to test effects of clusterin silencing using antisense oligonucleotides (ASOs) and short interfering double-stranded RNAs (siRNAs) on chemosensitivity in human lung cancer A549 cells.
    Methods: Clusterin immunostaining was evaluated in a tissue microarray of 149 spotted human lung cancers. The effects of clusterin ASO or siRNA treatment on clusterin expression and chemosensitivity to paclitaxel was examined in A549 cells in vitro while the ability of clusterin ASO to chemosensitize in vivo was evaluated in immunocompromised mice bearing A549 tumors.
    Results: More than 80% of human non-small cell lung cancers are immunoreactive for clusterin. Clusterin ASO or siRNA decreased clusterin mRNA expression in A549 cells >75% in a dose-dependent, sequence-specific manner, and significantly enhanced chemosensitivity to paclitaxel in vitro. Characteristic apoptotic DNA laddering was observed after combined treatment with ASO plus paclitaxel, but not with either agent alone. In vivo administration of clusterin ASO, compared to mismatch control oligonucleotide, synergistically enhanced the effects of paclitaxel or gemcitibine to significantly delay A549 tumor growth.
    Conclusion: These findings identify clusterin as a valid therapeutic target in strategies employing novel multimodality therapy for advanced lung cancer.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/therapy ; Animals ; Antimetabolites, Antineoplastic/pharmacology ; Antineoplastic Agents, Phytogenic/pharmacology ; Apoptosis ; Blotting, Northern ; Cell Line, Tumor ; Clusterin ; Coloring Agents/pharmacology ; DNA/genetics ; DNA Fragmentation ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Dose-Response Relationship, Drug ; Glycoproteins/genetics ; Glycoproteins/metabolism ; Glycoproteins/therapeutic use ; Humans ; Immunohistochemistry ; In Vitro Techniques ; Lung Neoplasms/drug therapy ; Lung Neoplasms/therapy ; Mice ; Molecular Chaperones/genetics ; Molecular Chaperones/metabolism ; Molecular Chaperones/therapeutic use ; Nucleotides/therapeutic use ; Oligonucleotide Array Sequence Analysis ; Paclitaxel/pharmacology ; RNA Interference ; RNA, Double-Stranded/genetics ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Tetrazolium Salts/pharmacology ; Thiazoles/pharmacology ; Time Factors
    Chemical Substances Antimetabolites, Antineoplastic ; Antineoplastic Agents, Phytogenic ; CLU protein, human ; Clu protein, mouse ; Clusterin ; Coloring Agents ; Glycoproteins ; Molecular Chaperones ; Nucleotides ; RNA, Double-Stranded ; RNA, Small Interfering ; Tetrazolium Salts ; Thiazoles ; Deoxycytidine (0W860991D6) ; DNA (9007-49-2) ; gemcitabine (B76N6SBZ8R) ; thiazolyl blue (EUY85H477I) ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2004-03-16
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2063563-1
    ISSN 1538-8514 ; 1535-7163
    ISSN (online) 1538-8514
    ISSN 1535-7163
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5750: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

    Gleave, Martin E / Zellweger, Toby / Chi, Kim / Miyake, Hideaki / Kiyama, Satoshi / July, Laura / Leung, Simon

    Investigational new drugs

    2003  Volume 20, Issue 2, Page(s) 145–158

    Abstract: The main obstacle to improved survival of advanced prostate cancer is our failure to prevent its progression to its lethal and untreatable stage of androgen independence. New therapeutic strategies designed to prevent androgen-independent (AI) ... ...

    Abstract The main obstacle to improved survival of advanced prostate cancer is our failure to prevent its progression to its lethal and untreatable stage of androgen independence. New therapeutic strategies designed to prevent androgen-independent (AI) progression must be developed before significant impact on survival can be achieved. Characterization of changes in gene expression profiles after androgen ablation and during progression to androgen-independence suggest that the various therapies used to kill neoplastic cells may precipitate changes in gene expression that lead to the resistant phenotype. Castration-induced increases in antiapoptosis genes, Bcl-2 and clusterin, help create a resistant phenotype, while antisense oligonucleotides can inhibit these adaptive cell survival mechanisms and enhance both hormone and chemotherapy. Ongoing efforts are necessary to identify additional molecular pathways mediating AI progression and chemoresistance, since complexities of tumor heterogeneity and adaptability dictate that optimal control over tumor progression will require multi-target systemic therapies.
    MeSH term(s) Adenocarcinoma/pathology ; Antineoplastic Agents, Phytogenic/therapeutic use ; Apoptosis/genetics ; Clusterin ; Genes, bcl-2/genetics ; Glycoproteins/genetics ; Humans ; Male ; Molecular Chaperones/genetics ; Oligonucleotides, Antisense ; Paclitaxel/therapeutic use ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/surgery ; Prostatic Neoplasms/therapy ; Receptors, Androgen/genetics ; Thionucleotides ; Up-Regulation/genetics
    Chemical Substances Antineoplastic Agents, Phytogenic ; CLU protein, human ; Clusterin ; Glycoproteins ; Molecular Chaperones ; Oligonucleotides, Antisense ; Receptors, Androgen ; Thionucleotides ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2003-02-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 604895-x
    ISSN 1573-0646 ; 0167-6997
    ISSN (online) 1573-0646
    ISSN 0167-6997
    DOI 10.1023/a:1015694802521
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1823: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top